Compare AbCellera Biologics Inc (ABCL) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Freshworks Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Freshworks Inc trades at $10.19 (market cap $2.87B). The key difference: Freshworks Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | FRSH | |
|---|---|---|
Market Cap | $2.35B | $2.87B |
Sector | Health | Technology |
52-Week High | $8.12 | $15.36 |
52-Week Low | $2.78 | $6.88 |
Enterprise Value | $1.99B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Freshworks (FRSH) trades at $10.38, up 0.39% with a bullish technical signal. The company shows strong revenue growth from $498M in 2022 to $839M in 2025, achieving profitability with a net margin of 20.69%. Recent news highlights AI-driven service platform adoption, including Vanquis selecting Freshservice. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook is positive due to accelerating revenue growth and expanding margins, though high EV/EBITDA of 48.15 suggests premium valuation. Risks include competitive pressures in SaaS and execution challenges in sustaining growth. Upside potential exists if the company maintains its earnings beat trend and capitalizes on AI integration demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
